To review recent advances in the understanding of the mechanisms of cisplatin nephrotoxicity. Factors affecting this toxicity and agents that may protect against it are discussed.
DATA SOURCES:
A MEDLINE search was used to identify pertinent literature including reviews. A manual search of bibliographies was performed to include all articles on the subject.
STUDY SELECTION:
All available data relating to the mechanisms, modifying factors, and management of cisplatin nephrotoxicity were assessed.
DATA EXTRACTION:
As limited human data are available, all animal studies were included. Articles with hypotheses or suggestions not backed by scientific data were excluded from review.
DATA SYNTHESIS:
Cisplatin is one of the most effective agents available for treating a variety of solid tumors. Nephrotoxicity is the dose-limiting factor for the use of this drug. Mechanisms for renal toxicity range from definitive histologic changes found in the proximal convoluted tubules to physiologic and biochemical alterations involving a decrease in mitochondrial respiratory function, enzymatic activity in the respiratory chain and glutathione peroxidase, and effects on cellular calcium homeostasis. Important factors related to nephrotoxicity include age, renal irradiation, and concurrent alcohol intake. Agents that appear promising in attenuating the nephrotoxic effects of cisplatin include loading with NaCl solution and/or mannitol, sodium thiosulfate, WR 2721, glutathione, probenecid, and many other compounds under active investigation.
CONCLUSIONS:
Cisplatin is a nephrotoxic drug; however, agents that may make cisplatin therapy more safe and rewarding will be available in the near future.
Get full access to this article
View all access options for this article.
References
1.
TognellaS. Pharmacological interventions to reduce platinum-induced toxicity. Cancer Treat Rev1990; 17: 139–42.
2.
DaugaardGAbildgaardUHolstein-RathlouNHBruunshuusIBucherDLeyssaiPP. Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther1988; 44: 164–72.
3.
DaugaardGAbildgaardULarsenS. Functional and histopathological changes in dog kidneys after administration of cisplatin. Renal Physiol1987; 10: 54–64.
4.
MavichakVWongNLMQuammeSAMagilABSuttonRALDirksJH. Studies on the pathogenesis of cisplatin-induced Hypomagnesemia in rats. Kidney Int1985; 28: 914–21.
5.
SugiyamaSHayakawaMKatoTHanakiYShimizUKOzawaT. Adverse effects of antitumor drug cisplatin on rat kidney mitochondria: disturbance in glutathione peroxidase activity. Biochem Biophys Res Commun1989; 159: 1121–7.
6.
BompartG. Cisplatin induced changes in cytochrome P 450, lipid peroxidation and drug metabolising enzyme activities in rat kidney cortex. Toxicology Lett1989; 48: 193–9.
7.
DeWittLMJonesTWMooreL. Stimulation of the renal endoplasmic reticulum calcium pump: a possible biomarker for platinum toxicity. Toxicol Appl Pharmacol1988; 92: 157–69.
8.
MavichakVCappinCMLWongNLMDirksJHWalkerVSuttonRAL. Renal magnesium wasting and hypocalciuria in chronic cisplatinum nephropathy in man. Clin Sci1988; 75: 203–7.
9.
BellinSLSelimM. Cisplatin-induced hypomagnesemia with seizures. A case and review of the literature. Gynecol Oncol1980; 30: 104–13.
10.
EvansRACarterJNGeorgePRWallsRS. The congenital magnesium-losing kidney. Report of two patients. Q J Med1981; 197: 39–52.
11.
SchilskyRLBarlockAOzolsRF. Persistent hypomagnesemia following cisplatin chemotherapy for testicular cancer. Cancer Treat Rep1982; 66: 1767–9.
12.
SchilskyRLAndersonT. Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. Ann Intern Med1979; 90: 929–31.
13.
LamMAdelsteinDJ. Hypomagnesemia and renal magnesium wasting in patients treated with cisplatin. Am J Kidney Dis1986; 8: 164–9.
14.
GuarinoAMMillerDSArnoldSTPritchardJBDavisRDUrbanekMAPlatinate toxicity: past, present and prospects. Cancer Treat Rep1979; 63: 1475–83.
15.
BianchettiMGKanakaCRidolfi-LuthyAWagnerHPHirtAPaunierLChronic renal magnesium loss, hypocalciuria and mild hypokalemic metabolic alkalosis after cisplatin. Pediatr Nephrol1990; 4: 219–22.
HrusheskyWJMShimpWKennedyBJ. Lack of age-dependent cisplatin nephrotoxicity. Am J Med1984; 76: 579–84.
18.
JudgeTG. The milieu interieur and aging. In: BrocklehurstJC, ed. Textbook of geriatric medicine and gerontology. 2nd ed.New York: Churchill Livingstone, 1978: 117–24.
19.
MoulderJEFishBL. Effect of sequencing on the combined toxicity of renal irradiation and cisplatin. NCI Monographs1988; 6: 29–33.
20.
StewartFALutsAOussorenYBeggACDeWittLBartelinkH. Renal damage in mice after treatment with cisplatin and X-rays: comparison of fractionated and single dose studies. NCI Monographs1988; 6: 23–7.
21.
EstepHShawWAWatlingtonCHobeRHollandWTuckerSt G. Hypocalcemia due to hypomagnesemia and reversible parathyroid hormone unresponsiveness. J Clin Endocrinol1969; 29: 842–8.
22.
HiltonPJLavenderSRothZJonesNF. Creatinine clearance in patients with proteinuria. Lancet1969; 2: 1215–6.
23.
DaugaardGRossingNRorthM. Effects of high-dose cisplatin on glomerular function in the human kidney. Cancer Chemother Pharmacol1988; 21: 163–7.
24.
BuamahPKHowellAWhitbyHHarpurESGesherA. Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma. Cancer Chemother Pharmacol1982; 8: 281–4.
25.
JonesBRBhallaRBMladekJKaleyaRNGrallaRJAlcockNWComparison of methods of evaluating nephrotoxicity of cisplatinum. Clin Pharmacol Ther1980; 27: 557–62.
26.
FrankJAChoykePLGirtonMEAustinHASievenpiperCInscoeSW. Gadolinium-DTPA enhanced dynamic MR imaging in the evaluation of cisplatin nephrotoxicity. J Computer Assisted Tomography1989; 13: 448–59.
27.
Al-SarrafMFletcherWOishiNPughRHewlettJSBalducciLCisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a Southwest Oncology Group study. Cancer Treat Rep1982; 66: 31–5.
28.
OzolsRFOstchegaYMyersCEYoungRC. High-dose cisplatin in hypertonic saline in refractory ovarian cancer. J Clin Oncol1985; 3: 1246–50.
29.
SobreroAGuglielmiAAscheleCRossoR. Current strategies to reduce cisplatin toxicity. J Chemother1990; 2: 3–7.
30.
DaugaardG. Cisplatin nephrotoxicity, experimental and clinical studies. Danish Med Bull1990; 37: 1–12.
31.
MannelRSStrattonJAMoranGRettenmaierMALiaoSYDisaiaPJ. Intraperitoneal cisplatin: comparison of antitumor activity and toxicity as a function of solvent saline concentration. Gynaecol Oncol1989; 34: 50–3.
32.
HayesDMCuitkovicEGolbeyRBScheinerEHelsonLKrakoffIH. High dose cisplatinum diammine dichloride. Amelioration of renal toxicity by mannitol diuresis. Cancer1977; 39: 1372–81.
33.
DaugaardGHolstein-RathlouNHLeyssaiPP. Effect of cisplatin on proximal convoluted and straight segments of the rat kidney. J Pharmacol Exp Ther1988; 224: 1081–5.
34.
Daley-YatesPTMcBrianDCH. Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumor activity of cisplatin. Biochem Pharmacol1984; 33: 3063–70.
HowellSBTaetleR. The effect of sodium thiosulphate on cis-dichlorodiammine platinum (II) toxicity and antitumor activity in the L1210 leukemia. Cancer Treat Rep1980; 40: 611–6.
HowellSBPfeifleCWungWOlshenRALucasWEYonJLIntraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med1982; 97: 845–51.
39.
GoelRClearySMHortonCKirmaniSAbramsonIKellyCEffect of sodium thiosulfate on the pharmacokinetics and toxicity of cisplatin. J Natl Cancer Inst1989; 81: 1552–60.
40.
TreskesMHolwerdaVKleinIPinedoHMVan der VughWJF. The chemical reactivity of the modulating agent WR 2721 (Ethiofos) and its main metabolites with the antitumor agents cisplatin and carboplatin. Biochem Pharmacol1991; 42: 2125–30.
41.
TreskesMBovenEHolwerdaVPinedoMWimJF. Time-dependence in the selective modulation of cisplatin-induced nephrotoxicity by WR-2721 in the mouse. Cancer Res1992; 52: 2257–60.
42.
GloverDGrabelskySFoxKWeilerCCannonLSlickJ. Clinical trials of WR-2721 and cis-platinum. J Radiation Oncol Biol Phys1989; 16: 1201–4.
43.
ZuninoFPratesiGMicheloniACavallettiESalaFTofanettiD. Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem Biol Interactions1989; 70: 89–101.
44.
JacobsCKaubischSHalseyJ. The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer1991; 67: 1518–24.
45.
RossDAGaleGR. Reduction of renal toxicity of cischloro diammine platinum (II) by probenecid. Cancer Treat Rep1979; 63: 781–7.
46.
ReznikLMyazinaEMShakchmatovaEIGambaryanSPBrovtskyVKNatochinYV. The prevention of cisplatin induced renal dysfunction by hydroxyl-containing dithiocarbamates. Br J Cancer1991; 63: 234–6.
47.
QaziRChangAYCBorchRFMontineTDedonPLoughnerJPhase I clinical and pharmacokinetic study of diethyldithiocarbamate as a protector from toxic effects of cisplatin. J Natl Cancer Inst1988; 80: 1486–8.
48.
WebbM. Binding of cadmium ions by rat liver and kidney. Biochem Pharmacol1972; 21: 2751–65.
49.
NordbergGF. Effect of acute and chronic cadmium exposure of the testicles of mice. Environ Physiol1971; 1: 171–87.
50.
AkiraAMasahikoS. Prevention of lethal and renal toxicity of cis-diammine dichloroplatinum (II) by induction of metallothionein synthesis without compromising its antitumor activity in mice. Cancer Res1987; 47: 983–7.
51.
KondoYSatohMImuraNAkimotoM. Effect of bismuth nitrate given in combination with cis-diamminedichloroplatinum (II) on the antitumor activity and renal toxicity of the latter in nude mice inoculated with human bladder tumor. Cancer Chemother Pharmacol1991; 29: 19–23.
HayashiTVatanabeYKamanoKKitayamaRMurantiTYasudaT. Protective effect of piperacillin against the nephrotoxicity of cisplatin in rats. Antimicrob Agents Chemother1989; 33: 513–8.
54.
SatohMNaganumaAInuraN. Deficiency of selenium intake enhances manifestation of renal toxicity of cis-diammine dichloro platinum in mice. Cancer Res1987; 47: 983–7.
